Canaccord Genuity Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $44
Benzinga Newsdesk 20 hours ago
Analyst RatingsNewsInitiationPrice Target
Canaccord Genuity analyst Edward Nash initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $44.
Canaccord Genuity analyst Edward Nash initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Buy rating and announces Price Target of $44.